Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us prof. dr. H.J. (Hiddo) Lambers Heerspink
University Medical Center Groningen

prof. dr. H.J. (Hiddo) Lambers Heerspink

Clinical Pharmacologist
Profile picture of prof. dr. H.J. (Hiddo) Lambers Heerspink
Telephone:
E-mail:
h.j.lambers.heerspink umcg.nl

Publications

Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Authors’ Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?

Canagliflozin and iron metabolism in the CREDENCE trial

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Press/media

Finerenone Improves UACR in T1D, CKD

'Nieuw' medicijn vermindert nierschade bij diabetespatiënten

Bayer Aktie: Neue Finanzchefin und Studienerfolg

Kidney drug trial raises hopes for new type 1 diabetes treatment

Hoe afslankmedicijnen het hele lichaam veranderen: ‘Mijn hoofd roept niet meer om eten’

智康弘义宣布SC0062临床II期糖尿病肾病队列研究达到12周主要终点 | 项目进展

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte